Safety profile of adenosine stress perfusion imaging: Results from the adenoscan multicenter trial registry  by Cerqueira, Manuel D. et al.
384
C4
Safty
Profil of Adnosin Strss Prfusion Imaging : Rsults From
th Adnoscan Multicntr Trial R istry
9
MANUEL D. CERQUEIRA,
MD, FACC, MARIO S
. VERANI . MD, FACC,*
MARKUS SCHWAIGER, MD,
FACC,t JAEKYEONG HEO, MD„
ABDULMASSIH S .
ISKANDRIAN, MD,
FAM AND
THE INVESTIGATORS OF THE MULTICENTER ADENOSCAN TRIAL§
Sattl, Washington, Houston, Txas ; Philadlphia, Pnnsylvania
. Ann Arbor, Michigan
Objctivs. Th purpos of this study was to dtrmin th
safty of adnosin infusion at
140 pWkg pr min in conjunction
with radionuclid Imaging In 9,256 conscutiv patints .
Background. Adnoslat products maximal myocardial hypr-
mia dirctly with a rapid onst of action
. In addition, whn usd
in conjunction with radionuclid prfusion imaging, it has provn
fficacy for th diagnosis of coronary artry disas in patints
unabl to xrcis. Bcaus th ultrashort half-lif (<10 s) allows
dos titration and rapid rvrsal of sid ffcts, it may b safr
than othr availabl pharmacologic agnts .
Mthods. Patints wr prospctivly ntrd at 21 clinical
sits . Information on safty and advrs
vnts during and
immdiatly aftr adnosin infusion was maintaind in th Ad-
noscan Multicntr Trial Rgistry .
Rsults. Th infusion protocol was compltd in 80% of
patints, rquird dos rduction in
13% and was trminatd
arly In 7%. Intrprtabl imaging studis
wr obtaind in
.7% of patints, and 0.8% of patints rcivd aminophyllin .
Pharmacologically inducd coronary artry hyprmia is
bing usd with incrasing frquncy in conjunction with
radionuclid prfusion imaging for th dtction of coronary
stnoss and risk stratification in patints with suspctd or
known coronary artry disas who ar unabl to prform
adquat lvls of xrcis
. Extnsiv data on fficacy and
safty hav bn acquird with oral and intravnous dipyr-
idamol (1-7),
which incrass coronary blood flow (8) by
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Minor and wll tolratd sid ffcts wr rportd in 81 .1% of
patip-*s . Thr wr no daths, on myocardial infarction, svn
pisods of svr bronchospasm and on pisod of pulmonary
dma. Transint atriovntricular (AV) nod block occurrd in
706 patints (first-dgr in 256, scond-dgr in 378 and third-
dgr in 72) and rsolvd spontanously in most patints (n =
508) without altration in th adnosin infusion . Thr wr no
sustaind pisods of AV block . Patints >70 yars of ag had an
incrasd risk of dvloping AV block (ag <70, 7.05% vs . L,70,
9.44%, p = 0 .001, rlativ risk 1 .37) .
Conclusions . Adnosin infusion is saf . Vasodilator and ng-
ativ dromotropic sid ffcts ar gnrally wll tolratd . Srious
sid ffcts ar rlativly rar, and thy rvrs with trmination
of adnosin infusion . Intrprtabl radionuclid studis wr
obtaind in 98 .7% of patints and aminophyllin rvrsal was
sldom rquird .
(I Ain Coll Cardiol 1994,23 .384-9)
allowing xtracliular accumulation of ndognously pro-
ducd adnosin
. Dirct intravnous infusion of adnosin
has also bn shown to incras coronary blood flow (9,10) .
Additionally, in combination with thallium-201 prfusion
imaging, it has a snsitivity and spcificity for dtcting
coronary artry disas comparabl to that obtaind with
xrcis thallium-201 scintigraphy (11-21) . Adnosin pro-
ducs maximal myocardial hyprmia dirctly, has a rapid
onst of action and an ultrashort half-lif (< 10 s) that allows
dos titration and rapid rvrsal of sid ffcts (22) .
Th Adnoscan Multicntr Trial Rgistry was a prospc-
tiv, opn labl phas III trial using fixd dos, continuous
intravnous infusion of adnosin in patints rfrrd for
clinically indicatd diagnostic radionuclid prfusion imag-
ing who wr unabl to prform
xrcis strss. From this
rgistry, w rport on th frquncy of arly advrs vnts
(during and immdiatly aftr adnosin infusion), thir
svrity and th rspons rquird in 9,256 conscutiv
patints . In 1,067 patints, w also rcordd dlayd or
rcurrnt advrs vnts during th immdiat 24-h priod
aftr infusion .
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Mthods
Btwn January 4, 1989 and March 13, 1992, a total of
9.256 conscutiv patints wr prospctivly nrolld
. All
patints gav informd consnt and th protocol was ap-
provd by th institutional rviw board on human rsarch
at ach participating cntr. A complt cardiovascular
history was obtaind and rcordd for ach patint on
nrollmnt . Patints wr ntrd at 21 clinical sits . All
information on safty and advrs vnts during and imm-
diatly aftr adnosin infusion was prospctivly rcordd
on standardizd forms and maintaind in a cntral rgistry .
Cohorts from this rgistry hav bn includd in prior
rports (11-18) .
Patint slction. Patints with known or suspctd cor-
onary artry disas rfrrd for clinically indicatd radio-
nuclid prfusion imaging who wr unabl to prform
xrcis strss wr ligibl for nrollmnt. Excludd wr
patints with hypotnsion (systolic blood prssur
<80 mm Hg), asthma, dcompnsatd or chronic obstruc-
tiv pulmonary disas that did not allow trmination of
bronchodilator thrapy, caffin ingstion within 24 h, s-
vr aortic stnosis, unstabl angina or acut myocardial
infarction within 24 h of th study. Each patint was moni-
tord mid qustiond bfor, during and immdiatly aftr
trmination of adnosin infusion, spcifically for th occur-
rnc of th following advrs vnts : shortnss of brath or
dyspna, atriovntricular (AV) block . hypotnsion
. arrhyth-
mias, chst pain, ST sgmnt dprssion on th lctrocar-
diogram (ECG), flushing, gastrointstinal discomfort, had-
ach, light-haddnss, nrvousnss and nausa . All
advrs vnts wr gradd on th basis of clinical svrity
by th physician invstigators as mild,
modrat or svr
and rcordd on standardizd forms . Each vnt was also
ratd as unrlatd or as dfinitly, probably, possibly rlatd
to adnosin infusion. Episods of first, scond or third
dgr AV block wr dsignatd as mild, modrat or
svr, rspctivly . Finally, th rspons to ach raction
was codd as tolratd without dosag adjustmnt, tolratd
with dosag adjustmnt, rquird trmination of adnosin
infusion or rquird rvrsal with aminophyllin . Amino-
phyllin administration was a clinical dcision mad by
individual physicians .
Adnosin infusion protocol. Adnosin (Adnoscan,
Mdco Rsarch, Inc .) was infusd at 140 gg/kg pr min
through a priphral vnous cathtr, using an accurat
infusion pump ovr 6 min (total dos 0 .84 mg/kg body
wight) as shown in Figur 1 . Aftr 3 min of infusion, th
radionuclid prfusion tracr was administrd intrav-
nously in th contralatral arm in most patints and th
infusion continud for an additional 3 min
. Patints with
poorly tolratd sid ffcts had th adnosin dos d-
crasd or th infusion trminatd, dpnding on th svr-
ity of th ffcts . Th rat of dos rduction and th dcision
to trminat wr dtrmind by individual physicians on
th basis of prcivd clinical risk
. Whnvr possibl, th
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Figur 1
. Adnosin infusion protocol for pharmacologic strss in
conjunction with radionuclid prfusion imaging
. Prfusion agnts
wr administrd arlir than 3 min in th prsnc of ischmia or
intolrabl sid ffcts and th infusion was continud for an
additional minut to maintain maxima ; LUrOilury blood flow . Infu-
sion rquirs a highly accurat pump systm
. BP = blood prssur :
EC6 = lctrocardiogram : HR = hart rat
; IN . = intravnous .
radioisotop was injctd and th adnosin infusion main-
taind for at last an additional minut . Prsistnt symp-
toms, dspit trmination of th infusion, wr managd by
physicians as clinically indicatd with aminophyllin (an
adnosin rcptor antagonist administrd at 75 mg ovr
I min to a maximal dos of 225 mg) . Nitroglycrin could b
administrd to patints with prsistnt chst pain not r-
sponding to aminophyllin .
Thallium-201 was th prfusion agnt usd in th majority
of patints (89.7%), but 4
.2% rcivd tchntium-99m ss-
tamibi, 3 .7% rcivd nitrogn-13 ammonia or rubidium-82
and 2.3% rcivd othr agnts. Th ECG was monitord
continuously and blood prssur and hart rat wr ma-
surd at baslin and vry minut during th adnosin
infusion and for a minimum of 5 min aftr it was trminatd .
Dlayd advrs vnts . At fiv mdical cntrs, 1,067
conscutiv patints undrgoing thallium imaging wr pro-
spctivly valuatd ovr 24 h aftr th trmination of
adnosin infusion to charactriz safty byond th imm-
diat imaging prioC . In-patints wr qustiond dirctly
and thir charts rviwd. Outpatints wr contactd by
tlphon intrviw
. Advrs vnts wr classifid by
invstigators as dlayd (rportd during 24 h of follow-up
but not rportd during th infusion) or rcurrnt (rportd
during th infusion and rcurring during th 24-h follow-up
priod). Dlayd or rcurrnt vnts wr furthr clinically
gradd as bnign (mild or modrat in svrity and with
spontanous rsolution) or potntially significant (svr and
without spontanous rsolution) .
Statistical analysis
. All valus ar xprssd as th man
valu ± I SD
. Patint prcntags ar xprssd rlativ to
th numbr of patints who had availabl data for th
spcific variabl
. Diffrncs btwn groups and hmody-
namic changs ovr tim wr dtrmind by i tst compar-
ison or analysis of varianc (ANOVA) for rpatd ma-
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coronary artry bypass graft ; CAD = coronary artry disas.
CHF - cogstiv hart failur ; MI = myocardial infarction
.
curs. A p valu < 0.05 was considrd significant . Whn
multipl comparisons wr prformd, th Bonfrroni cor-
rction was usd to dtrmin th p valu rquird for
statistical significanc . Th rlation btwn th occurrnc
of AV block and various clinical and hmodynamic variabls
was xplord using univariat and multivariat analysis . For
univariat analysis, discrt variabls wr compard by t
tsts and continuous variabls by chi-squar analysis . Vari-
abls with p < 0.05 by univariat analysis wr ntrd into
th stpwis logistic rgrssion analysis .
Rsults
Patint charactristics . Tabl l lists th charactristics of
th patints nrolld in this protocol. In gnral, ths
charactristics ar typical of patints rfrrd for diagnostic
radionuclid prfusion imaging who ar unabl to prform
xrcis strss .
H ynatnic rspons. Figur 2 shows th hart rat
and blood prssur rspons at baslin and during th 6 min
of adnosin infusion in patints complting th 6-min infu-
sion. Th typical hmodynamic rspons was a modst
rductio . in systolic and diastolic blood prssur with a
compnsatory incras in hart rat . Svr hypotnsion or
paradoxic hyprtnsion was infrqunt in ths patints, as
wll as in thos who had a dos rduction or trmination .
Hart rat incrasd significantly during ach minut of
infusion xcpt btwn th 5th and 6th min. Systolic and
diastolic blood prssur dcrasd during ach minut of
infusion xcpt that systolic blood prssur rmaind un-
changd btwn baslin and minut 1 . Th following
baslin to maximal changs wr rcordd
: hart rat
incrasd from 72 .6 ± 13
.7 to 86.3 ± 27.3 bats/min, systolic
blood prssur dcrasd from 140.9 ± 24.3 to 131
.4
Figur 2 . Changs in systolic and diastolic blood prssur (OP) and
hart rat in patints who compltd th full adnosin infusion
protocol (n = 6,921) at 140 taglkg pr min ovr 6 min. *p < 0
.0001 in
comparison with prior tim intrval . bpm = bats pr minut .
27
.3 mm Hg and diastolic blood prssur dcrasd from
79.9 11 .9 to 71 .9 ± 14.2 mm Hg .
Protocol compltion . As shown in Figur 3, th 6-min
140-jug/kg pr thin adnosin infusion protocol was com-
pltd in 7,226 patints (80%), rquird dos rduction in
1
.165 patints (13%) and was trminatd arly in 664 patints
(7%) . Aminophyllin was givn to 71 patints (0.8%) . D-
spit adnosin dos rduction or arly trmination, radio-
isotop was injctd and th infusion continud for an
additional priod in 98 .7% of patints . In som patints . th
occurrnc of significant ECG changs or chst pain was th
rason for th arly trmination or dos rduction .
Figur 3. Th 6-min high dos adnosin infusion protocol was
compltd in 7,226 patints (80%) . Th short half-lif of adnosin
allowd dos rduction in 1,165 patints (13%) who xprincd
intolrabl sid ffcts .
Trminatd Early
n=666 (7%)
Dos Rducd
	
Compltd
no1,165 (13%) nw7,226 (80%)
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Tabl 1 . Patint Charactristics
Ag (yr)
Man ± SD
65 .0 ± 11 .6
>65
55%
Gndr ( 1 0
Mal
54
Fmal
46
Rac (%)
Whit
85 .4
Black
11 .9
Othr
2.8
Risk factors (%)
Hyprtnsion
56 .6
Cardiomyopathy
5 .5
CAD
provd
49 .3
Suspctd
50.7
CHF
14 .1
Prior MI 23 .1
Prior CABO 17 .3
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Tabl 2
. Frquncy of Advrs Evnts (>2%) During Adnosin
Infusion (n = 9,256)
AV = atriovntricular : 61 gastrointstinal : SOB shortnss of brath :
TNJ ~ throal, nck,, jaw : U E uppr xtrmily .
Advrs vnts. Thr , wr no daths in 9,256 patint
studis. A total of 17,191 advrs vnts wr rportd by
7,507 patints (81 .1%)
; no advrs vnts wr rportd by
1,749 patints (183% Patints without advrs vnts had
fwr hmodynamic changs than did patints rporting
vnts . Th occurrnc of individual advrs vnts ar
prsntd in Tabl 2 for thos vnts with >2% frquncy .
Of th advrs ractions, 78 .4% wr clinically gradd by
invstigators as mild, 9 .6% as modrat and 4.7% as svr .
Th rlation btwn rportd vnts and adnosin infusion
was gradd as rlatd in th majority (dfinitly rlatd in
85% and probably rlatd in 9 .6%) .
Cardiovascular or othr potntially significant clinical
vnts includd : hypotnsion in 163 (1 .8%), bradycardia in
23 (0.2%), bronchospasm in 12 (0 .1%, of which svn
pisods wr classifid as svr), hyprtnsion in 5
(0.05%), myocardial infarction in 1 (0%) and pulmonary
dma in 1 (0%) . Th. singl patint who dvlopd myocar-
dial infarction bad undrgon prcutanous transluminal
coronary angioplasty of th lft antrior dscnding artry 3
days bfor adnosin scintigraphy . During angioplasty, a
svr circumfrntial dissction was notd and chst pain
was xprincd but not rportd by th patint in th
nsuing 72 h .
As shown in Figur 4 from th stpwis logistic rgrs-
sion analysis final modl, th rlativ risk of having any
advrs vnt rgardlss of svrity was incrasd in womn
(odds ratio 1 .78), patints with body wight abov th
mdian (odds ratio 1 .47) and patints youngr than th
mdian ag (odds ratio 1 .52) .
Atriovntricular block. Atriovntricular block of any
typ occurrd in 706 (7 .6%) of all patints studid. Of ths,
256 had first dgr block, 378 had scond dgr block and
only 72 patints (0 .78% of all patints nrolld) xprincd
third dgr AV block . Fiv hundrd ight pisods of AV
block slf-trminatd without rquiring intrvntions and
133 rsolvd with a rduction of th dos . Only 57 patints
had adnosin administration trminatd bcaus of AV
block. Six patints with AV block rcivd aminophyllin,
Risk Factors
Fmal Gndr
Incrasd
wight
Mals >82 kg
Fmals >72 kg
Youngr Ag
Mals 05
Fmals <_68
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Figur 4
. Th rlativ risk of having any sid ffcts during ad-
nosin infusion as dtrmind by stpwis logistic rgrssion anal-
ysis was modstly incrasd in womn, patints
whos body wight
was highr than
th mdian body wight and thos whos ag was
lss than th mdian ag
.
but in all cass, th pisods had alrady slf-trminatd .
Thr wr no diffrncs in th occurrnc of ischmia
(prfusion dfcts or ischmic ECG changs) btwn pa-
tints with and without AV block. Thus, ths pisods of
AV nod block probably rprsnt a dirct adnosin ffct
on th conduction systm rathr than a manifstation of
ischmia .
Univariat analysis of baslin clinical and ECG charac-
tristics, mdications (including bta-adrnrgic and calcium
blockrs) and patint ag, ntrd as a continuous variabl,
idntifid only ag as a prdictor of AV block . Sparat
analyss wr also prformd ntring ag as a discrt
variabl, starting at ag :550 or >50 yars and incrasing by
5-yar intrvals to ag 75 yars . Th bst sparation by ag
occurrd for patints <70 yars (63% of all patints tstd)
vrsus patints :00 yars (37%) (AV block incidnc of
7.05% vs. 9.44%, p < 0 .001). Whn this ag dichotomy was
ntrd into th logistic rgrssion analysis modl, th
rlativ risk for AV nod block was modstly incrasd
(odds ratio 1 .37, 95% confidnc intrvals of 1 .17 to 1 .61) .
Bta- and calcium channl blockrs and conduction systm
abnormalitis on th baslin ECG wr not prdictors of
AV nod block .
Dlayd or rcurrnt advrs vnts. in th 1,067 patints
monitord for 24 h, thr wr 142 dlayd vnts and 107
rcurrnt vnts rportd for a total of 23% . Of th 142
dlayd vnts, 21 vnts in 17 patints wr considrd
potntially significant and includd hadach (n = 6), gas-
trointstinal discomfort (n = 3), xtrmity discomfort
(n 3), hypotnsion (n = 2), chst pain (n = 2), parsthsia
(n I), asthnia (n = 1), bradycardia (n = I), light-
haddnss/dizzinss (n = 1) and inability to walk (n = I) .
Th majority of ths vnts rsolvd spontanously or with
minimal intrvntion and wr judgd by physicians to b
unrlatd or not clarly du to th adnosin infusion .
No . %
Flushing 3 .377
36 .5
SOB/dyspna
3,260
35 .2
Chst pain
3,207 34 .6
GI discomfort
1 .352 14 .6
Hadach 1,318
14 .2
TNJ discomfort 1,178
IIA
Lighi-haddnss
78-3, 8 .5
AV block
706 7 .6
ST-T changs
531 5 .7
Arrhythmia 309
3 .3
UE discomfort 213 2 .3
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Discussion
Ths rsults show that adnosin infusion in conjunction
with radionuclid prfusion imaging is saf in comparison
with dipyridamol infusion or xrcis strss tsting . Thr
wr no daths in 9,256 patints and srious sid ffcts wr
rar and rvrsd with trmination of th infusion . Amino-
phyllin rvrsal was sldom rquird . Although thr was a
statistically significant incrasd risk for total sid ffcts in
womn, youngr patints and thos abov th mdian body
wight, th rlativ risk ratios ar low and do not allow
clinical prdiction for advrs vnts in an individual pa-
tint . Dlayd or rcurrnt advrs ractions in th 24 h aftr
infusion wr infrqunt and gnrally considrd unrlatd
to th adnosin infusion .
Comparison with dipyridamol . Safty and advrs rac-
tions in conjunction with dipyridamol-inducd hyprmia
hav bn rportd in two larg sris of patints (5,6) .
Ranhosky t al . (5) rtrospctivly acquird safty data in
3,911 patints rciving standard dos dipyridamol infusion
and rportd two daths and four myocardial infarctions .
Picano t al . (6) prospctivly acquird similar information
in 9,122 patints rciving high dos dipyridamol with
chocardiography and rportd on dath and two myocar-
dial infarctions. Using continuous, high dos adnosin
infusion, w obsrvd no daths and on myocardial infarc-
tion . Th myocardial infarction occurrd in a patint who
had a svr coronary artry dissction during angioplasty
with subsqunt chst pain and who rtrospctivly was not
a good candidat for adnosin pharmacologic tsting b-
caus of his unstabl condition.
Bcaus of th short half-lif of adnosin, sid ffcts
rvrs on trmination or a dcras in th rat of th
infusion
. Aminophyllin, an adnosin rcptor antagonist,
is usd infrquntly. Only 71 patints (0 .8%) in our rgistry
rcivd aminophyllin as opposd to 11
.6% in th rport by
Ranhosky t al
. (5) and its routin us in all patints by
Picano t al . (6) . In 20% of our patints rciving adnosin,
advrs vnts wr tratd by simply dcrasing th dos
.
Such dos titration is not possibl with dipyridamol, which
has a long half-lif (>30 min) that dos not allow dos
adjustmnt and rquirs aminophyllin to rvrs sid f-
fcts
. Th administration of aminophyllin may itslf caus
advrs vnts
. Picano t al . (6) rportd clinically signifi-
cant sid ffcts du to aminophyllin rvrsal in 17 patints
:
13 pisods of ST sgmnt lvation associatd with
chocardiographic wall motion abnormalitis in patints
with variant angina, 3 pisods of hypotnsion/bradycardia
and I pisod of atrial fibrillation
. Although minor sid
ffcts ar mor frqunt with adnosin, thy ar wll
tolratd and rsolv with trmination of th infusion
.
Considring that patints undrgoing pharmacologic
strss tsting ar gnrally oldr and mor dbilitatd than
thos undrgoing xrcis strss, ths rsults suggst that
both dipyridamol and adnosin ar saf and that svr
cardiac vnts ar rar using ithr agnt
. Adnosin offrs
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th following advantags : rapid onst of action, provn
potncy as a dirct coronary vasodilator, th ability to
rapidly modulat its pharmacologic ffcts through dos
adjustmnt, short half-lif and a low incidnc of aminophyl-
lin administration for rvrsal .
Incidnc of advrs vnts by ag, gndr and body
wight. During intravnous dipyridamol infusion, a highr
frquncy of total sid ffcts has bn rportd in womn
rlativ to mn and in obs patints (7,23) . W rport
similar findings with th us of adnosin . Youngr patints
wr mor likly to rport advrs vnts than wr oldr
patints . Th rason for this ag diffrnc is not obvious
and may b rlatd to diffrncs in prcption, adnosin
rcptor snsitivity or adnosin mtabolism .
Atriovntricular block . This occurrd in 7.6%% of patints
but trminatd spontanously in most . and thr wr no
prolongd pisods in any patint . Th incras in rlativ
risk in patints L-70 yars (9.44%) vrsus patints <70 yars
(7 .05%) dos not allow prdiction of risk in an individual
patint . Patints taking bta- or calcium channl blockrs
wr not at incrasd risk .
Th obsrvation that prfusion dfcts and ischmic ECG
changs did not prdict AV block suggsts that th block
was a transint and dirct pharmacologic ffct of adnosin
on th AV nod . This is wll known and undrlis th
currnt indication of adnosin as an ffctiv drug for
tratmnt of supravntricular tachycardia (22) . Spcial car
must b takn to infus adnosin at a constant rat during
its us with radionuclid prfusion imaging . It is optimally
infusd by using an accurat and prfrably computrizd
pump systm that allows th infusion rat to b dcrasd
without bing compltly stoppd
. Stopping th infusion
compltly bfor rducing th dos rsults in a rapid
rvrsal of th hyprmia and it may tak I to 2 min to rach
maximal hyprmia at th nw dos
. Rapid injction and
flushing of th radiopharmacutical agnt through th intra-
vnous tubing bing usd for th adnosin infusion should
b avoidd bcaus this bolus ffct will caus high blood
lvls and incras th risk of AV nod block . Th transint
ffcts of adnosin on th conduction systm ar rportd
to b unrsponsiv to atropin .
Dlayd or rcurrnt advrs vnts . Th occurrnc of
dlayd or rcurrnt sid ffcts in th 24 h aftr adnosin
infusion was low and in most cass considrd unrlatd to
th prior adnosin infusion . Bcaus adnosin is an ndo-
gnous substanc with a plasma half-lif of <10 s, it is
difficult to attribut dlayd or rcurrnt advrs vnts to
its us . It is mor likly that th rportd vnts wr rlatd
to th patints' ongoing mdical problms, changs in md-
ications or changs in managmnt
.
Conclusions. Ths prospctiv findings in a larg group
of patints stablish th ovrall safty of adnosin pharma-
cologic hyprmia in conjunction with radionuclid prfu-
sion imaging.
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Addndum
Sinc compltion of nrollmnt of th 9,256 patints
prsntd in this rport, approximatly 1,800 additional
patints hav bn nrolld and thr was on rportd
dath aftr a total patint nrollmnt of
1 1,000 .
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